Jean H. Hoffman-Censits, Burles Avner Johnson, Noah M. Hahn, Woonyoung Choi, Armine Smith, Nirmish Singla, David James McConkey, and Max R. Kates Journal of Clinical Oncology Share on Facebook. Opens ...

Fifty-five patients were enrolled onto the study, and 53 were assessable. The major toxicities included grade 3 and 4 acute neutropenia (32% and 43%, respectively) and grade 3 and 4 esophagitis (32% ...

The role of platinum doublet as the chemotherapy backbone for first-line treatment for extensive-stage small cell lung cancer (ES-SCLC) has been well established for decades. Immunotherapy has been ...

Background and Aim: Systemic treatments of advanced hepatocellular carcinoma (AHCC) have offered marginal clinical benefits. Recently, Italian investigators reported that etoposide and epirubicin ...

IMpower133 is a Phase III, multicenter, double-blinded, randomized placebo-controlled study evaluating the efficacy and safety of Tecentriq in combination with chemotherapy (carboplatin and etoposide) ...

New Cornell research is providing a fresh view into the ways a common chemotherapy agent, etoposide, stalls and poisons the essential enzymes that allow cancer cells to flourish. The findings, from ...